Bradley L. Campbell - 20 Jan 2026 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
President and CEO, Director
Signature
/s/ Christian Formica, Attorney-in-Fact
Issuer symbol
FOLD
Transactions as of
20 Jan 2026
Net transactions value
-$615,682
Form type
4
Filing time
22 Jan 2026, 19:26:57 UTC
Previous filing
30 Dec 2025
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Campbell Bradley L President and CEO, Director 47 HULFISH STREET, PRINCETON /s/ Christian Formica, Attorney-in-Fact 22 Jan 2026 0001400971

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Options Exercise $457,500 +75,000 +7.3% $6.10 1,096,180 20 Jan 2026 Direct
transaction FOLD Common Stock Sale $1,073,182 -75,000 -6.8% $14.31 1,021,180 20 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FOLD Stock Options (right to buy) Options Exercise $0 -75,000 -100% $0.000000 0 20 Jan 2026 Common Stock 75,000 $6.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.30 to $14.32 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 All of the options were fully vested and exercisable as of the transaction date.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025.